Corcept Therapeutics Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $43.0M | $-31.8M | $19.7M | $35.1M | $20.5M | $47.2M | $35.5M | $27.8M |
| Depreciation & Amortization | — | $598.0K | — | — | $462.0K | — | — | $120.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | $52.0K |
| Stock-Based Compensation | — | $23.0M | — | — | $21.8M | — | — | $13.2M |
| Net Cash from Operating Activities | $33.5M | $-16.8M | $54.5M | $44.3M | $4.8M | $73.3M | $41.2M | $23.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.5M | $201.0K | $0 | $57.0K | $104.0K | $1.6M | $416.0K | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $4.5M | — | — | $-3.2M | — | — | $-9.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | $0 | — | — | $27.4M | — | — | $476.0K |
| Net Cash from Financing Activities | — | $760.0K | — | — | $-39.8M | — | — | $-543.0K |
| Net Change in Cash | — | $-11.8M | — | — | $-37.8M | — | — | $14.2M |
| Free Cash Flow | $31.0M | $-17.0M | $54.5M | $44.2M | $4.7M | $71.7M | $40.8M | $23.8M |